Inventor · disambiguated record
Li Li
Also filed as: Li li-jia
112 granted patents·166 pending applications·995 citations·filing 1995–2025
99Inventor score
Files withTHERAVANCE INC29AMGEN INC13INNOVENT BIOLOGICS SUZHOU CO LTD8CHENLAND NUTRITIONALS INC7MAMMEN MATHAI7
Top patents by PatentIndex Score
278 records- 0199US7288657B2Biphenyl compounds useful as muscarinic receptor antagonistsTHERAVANCE INC·Filed 2005·Granted Oct 30, 2007·71 cites·18 claims
- 0298US11247969B2Biphenyl compounds useful as muscarinic receptor antagonistsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2020·Granted Feb 15, 2022·6 cites·10 claims
- 0397US9580486B2Interleukin-2 muteins for the expansion of T-regulatory cellsAMGEN INC·Filed 2014·Granted Feb 28, 2017·47 cites·27 claims
- 0497US8053448B2Biphenyl compounds useful as muscarinic receptor antagonistsTHERAVANCE INC·Filed 2011·Granted Nov 8, 2011·24 cites·2 claims
- 0597US8034946B2Biphenyl compounds useful as muscarinic receptor antagonistsTHERAVANCE INC·Filed 2010·Granted Oct 11, 2011·28 cites·2 claims
- 0697US7910608B2Biphenyl compounds useful as muscarinic receptor antagonistsTHERAVANCE INC·Filed 2007·Granted Mar 22, 2011·32 cites·4 claims
- 0797US7585879B2Biphenyl compounds useful as muscarinic receptor antagonistsTHERAVANCE INC·Filed 2007·Granted Sep 8, 2009·35 cites·12 claims
- 0897US7550595B2Biphenyl compounds useful as muscarinic receptor antagonistsTHERAVANCE INC·Filed 2007·Granted Jun 23, 2009·37 cites·22 claims
- 0997US7521041B2Biphenyl compounds useful as muscarinic receptor antagonistsTHERAVANCE INC·Filed 2007·Granted Apr 21, 2009·27 cites·22 claims
- 1097US7491736B2Biphenyl compounds useful as muscarinic receptor antagonistsTHERAVANCE INC·Filed 2007·Granted Feb 17, 2009·29 cites·24 claims
- 1197US7265133B2Biphenyl compounds useful as muscarinic receptor antagonistsTHERAVANCE INC·Filed 2005·Granted Sep 4, 2007·65 cites·20 claims
- 1296US10570092B2Biphenyl compounds useful as muscarinic receptor antagonistsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Feb 25, 2020·8 cites·5 claims
- 1396US10343995B2Biphenyl compounds useful as muscarinic receptor antagonistsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Jul 9, 2019·9 cites·23 claims
- 1496US9932380B2Interleukin-2 muteins for the expansion of T-regulatory cellsAMGEN INC·Filed 2017·Granted Apr 3, 2018·23 cites·23 claims
- 1596US9732134B2Method of treating graft versus host disease using IL-2 muteinsAMGEN INC·Filed 2012·Granted Aug 15, 2017·50 cites·3 claims
- 1696US9452161B2Biphenyl compounds useful as muscarinic receptor antagonistsMAMMEN MATHAI·Filed 2016·Granted Sep 27, 2016·11 cites·9 claims
- 1796US7803812B2Biphenyl compounds useful as muscarinic receptor antagonistsTHERAVANCE INC·Filed 2009·Granted Sep 28, 2010·19 cites·30 claims
- 1895US10106503B2Biphenyl compounds useful as muscarinic receptor antagonistsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Oct 23, 2018·9 cites·25 claims
- 1995US9926272B2Biphenyl compounds useful as muscarinic receptor antagonistsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2016·Granted Mar 27, 2018·9 cites·7 claims
- 2095US9283183B2Biphenyl compounds useful as muscarinic receptor antagonistsMAMMEN MATHAI·Filed 2014·Granted Mar 15, 2016·12 cites·17 claims
- 2195US8912334B2Biphenyl compounds useful as muscarinic receptor antagonistsMAMMEN MATHAI·Filed 2013·Granted Dec 16, 2014·13 cites·6 claims
- 2295US8557997B2Biphenyl compounds useful as muscarinic receptor antagonistsMAMMEN MATHAI·Filed 2012·Granted Oct 15, 2013·13 cites·6 claims
- 2395US8273894B2Biphenyl compounds useful as muscarinic receptor antagonistsMAMMEN MATHAI·Filed 2012·Granted Sep 25, 2012·15 cites·14 claims
- 2495US8173815B2Biphenyl compounds useful as muscarinic receptor antagonistsMAMMEN MATHAI·Filed 2011·Granted May 8, 2012·15 cites·10 claims
- 2595US8017783B2Biphenyl compounds useful as muscarinic receptor antagonistsTHERAVANCE INC·Filed 2007·Granted Sep 13, 2011·17 cites·13 claims
- 2695US7629336B2Biphenyl compounds useful as muscarinic receptor antagonistsTHERAVANCE INC·Filed 2006·Granted Dec 8, 2009·29 cites·12 claims
- 2794US10829535B2Interleukin-2 muteins for the expansion of T-regulatory cellsAMGEN INC·Filed 2018·Granted Nov 10, 2020·5 cites·5 claims
- 2893US7524880B2Crystalline form of a substituted pyrrolidine compoundTHERAVANCE INC·Filed 2005·Granted Apr 28, 2009·23 cites·13 claims
- 2992US10851144B2Interleukin-2 muteins for the expansion of T-regulatory cellsAMGEN INC·Filed 2016·Granted Dec 1, 2020·16 cites·10 claims
- 3092US7728144B2Biphenyl compounds useful as muscarinic receptor antagonistsTHERAVANCE INC·Filed 2006·Granted Jun 1, 2010·20 cites·17 claims
- 3191US7851632B2Biphenyl compounds useful as muscarinic receptor antagonistsTHERAVANCE INC·Filed 2007·Granted Dec 14, 2010·14 cites·14 claims
- 3290US7868175B2Biphenyl compounds useful as muscarinic receptor antagonistsTHERAVANCE INC·Filed 2009·Granted Jan 11, 2011·11 cites·13 claims
- 3388US7071224B2Diphenylmethyl compounds useful as muscarinic receptor antagonistsTHERAVANCE INC·Filed 2005·Granted Jul 4, 2006·9 cites·21 claims
- 3488US2024327485A1Interleukin-2 muteins for the expansion of t-regulatory cellsAMGEN INC·Filed 2024·Application pending·0 cites
- 3587US8871201B2Stabilizing formulationsLI LI·Filed 2005·Granted Oct 28, 2014·14 cites·17 claims
- 3686US8501776B2Biphenyl compounds useful as muscarinic receptor antagonistsJI YUHUA·Filed 2010·Granted Aug 6, 2013·7 cites·13 claims
- 3786US7960385B2Guanidine-containing compounds useful as muscarinic receptor antagonistsTHERAVANCE INC·Filed 2008·Granted Jun 14, 2011·6 cites·24 claims
- 3886US7034132B2Therapeutic polypeptides, nucleic acids encoding same, and methods of useANDERSON DAVID W·Filed 2002·Granted Apr 25, 2006·25 cites·13 claims
- 3985US7109000B2Proteins and nucleic acids encoding sameCURAGEN CORP·Filed 2002·Granted Sep 19, 2006·23 cites·10 claims
- 4084US12258316B2Biphenyl compounds useful as muscarinic receptor antagonistsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2022·Granted Mar 25, 2025·0 cites·7 claims
- 4183US12297248B2Methods of treating graft versus host disease using IL-2 muteinsAMGEN INC·Filed 2022·Granted May 13, 2025·0 cites·6 claims
- 4283US7351718B2Substituted pyrrolidine and related compoundsTHERAVANCE INC·Filed 2006·Granted Apr 1, 2008·4 cites·12 claims
- 4383US7351717B2Substituted pyrrolidine and related compoundsTHERAVANCE INC·Filed 2006·Granted Apr 1, 2008·4 cites·31 claims
- 4483US7183292B2Substituted pyrrolidine and related compoundsTHERAVANCE INC·Filed 2004·Granted Feb 27, 2007·14 cites·23 claims
- 4582US6743898B2Monoclonal antibodies that suppress B cell growth and/or differentiationOCHSNER CLINIC FOUNDATION·Filed 2001·Granted Jun 1, 2004·21 cites·7 claims
- 4681US12421494B2Method for ex-vivo expansion of regulatory T cells with enhanced suppressive function for clinical application in immune mediated diseasesTHERAKOS DEVELOPMENT LTD·Filed 2024·Granted Sep 23, 2025·0 cites·12 claims
- 4780US8039489B2Guanidine-containing compounds useful as muscarinic receptor antagonistsTHERAVANCE INC·Filed 2011·Granted Oct 18, 2011·3 cites·18 claims
- 4879US8399488B2Biphenyl compounds useful as muscarinic receptor antagonistsJI YUHUA·Filed 2012·Granted Mar 19, 2013·3 cites·14 claims
- 4979US8013152B2Biphenyl compounds useful as muscarinic receptor antagonistsTHERAVANCE INC·Filed 2010·Granted Sep 6, 2011·3 cites·19 claims
- 5078US11331339B2Compound composition with function of promoting bone and joint health and application thereofCHENLAND NUTRITIONALS INC·Filed 2020·Granted May 17, 2022·1 cites·3 claims
Showing the top 50 of 278 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Li Li files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →